title: Application of the nuclear factor-κB inhibitor pyrrolidine dithiocarbamate for the treatment of endometriosis: an in vitro study.
abstract: This study demonstrated that pyrrolidine dithiocarbamate (PDTC), a potent nuclear factor-κB inhibitor, showed stronger inhibitory effects on nuclear factor-κB activation in endometriotic stromal cells than in normal endometrial stromal cells as determined by electrophoretic mobility shift assay and Western blot analysis. Pretreatment of endometriotic stromal cells with PDTC attenuated tumor necrosis factor-α-induced expressions of CD44s, matrix metalloproteinase-9, and vascular endothelial growth factor whereas reversed tumor necrosis factor-α-reduced expressions of tissue inhibitor of metalloproteinase-1 revealed by reverse transcriptase polymerase chain reaction and Western blot analysis, suggesting that PDTC may represent a novel therapeutic strategy for treatment of endometriosis.
authors.affiliation: Department of Obstetrics and Gynecology, Affiliated Hospital of Medical College of Qingdao University, Qingdao, Shandong, People's Republic of China. xzmzjj@163.com
authors.forename: Jing-jing
authors.initials: JJ
authors.lastname: Zhang
authors.forename: Zhi-ming
authors.initials: ZM
authors.lastname: Xu
authors.forename: Hong-ying
authors.initials: HY
authors.lastname: Dai
authors.forename: Xin-qiang
authors.initials: XQ
authors.lastname: Ji
authors.forename: Yu-ying
authors.initials: YY
authors.lastname: Duan
authors.forename: Chun-mei
authors.initials: CM
authors.lastname: Zhang
authors.forename: Dong-yan
authors.initials: DY
authors.lastname: Qin
mesh_terms: D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D016022:Case-Control Studies; D002478:Cells, Cultured; D004353:Drug Evaluation, Preclinical; D004715:Endometriosis / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D018960:Hyaluronan Receptors / Q000235:genetics / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000235:genetics / Q000378:metabolism; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism; D010048:Ovarian Cysts / Q000473:pathology; D010532:Peritoneal Diseases / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D011759:Pyrrolidines / Q000494:pharmacology / Q000627:therapeutic use*; D017154:Stromal Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D013859:Thiocarbamates / Q000494:pharmacology / Q000627:therapeutic use*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000235:genetics / Q000378:metabolism
chemical_list: D000975:Antioxidants; C497483:CD44 protein, human; D018960:Hyaluronan Receptors; D016328:NF-kappa B; D011759:Pyrrolidines; D013859:Thiocarbamates; D019715:Tissue Inhibitor of Metalloproteinase-1; C020972:pyrrolidine dithiocarbamic acid; D020780:Matrix Metalloproteinase 9